Jaguar health announces first patient dosed in short bowel syndrome with intestinal failure in investigator-initiated trial of crofelemer; proof-of-concept data potentially available h1 2025

Trial taking place at sheikh khalifa medical city , a flagship united arab emirates hospital and largest teaching medical center in abu dhabi crofelemer, jaguar's novel plant-based prescription drug, has been granted orphan drug designation by the fda and the european medicines agency for both sbs-if and mvid proof-of-concept (poc) data generated from this study could potentially lead to reimbursed early patient access in certain european countries for crofelemer for these rare/orphan diseases san francisco, ca / access newswire / february 3, 2025 / jaguar health, inc. (nasdaq:jagx) (jaguar) family companies napo pharmaceuticals (napo) and napo therapeutics today announced that the first short bowel syndrome with intestinal failure (sbs-if) patient has been dosed in the independent investigator-initiated pediatric poc trial (iit) of crofelemer, jaguar's novel plant-based antidiarrheal prescription drug. the first infant with microvillus inclusion disease (mvid) was dosed as part of the same iit two weeks ago.
JAGX Ratings Summary
JAGX Quant Ranking